Table 2.
Characteristics of Cancer Survivors With GH Deficiency in the KIGS Database, According to Tumor Subgroup
| Craniopharyngioma (RT) | Craniopharyngioma (No RT) | Medulloblastoma | Leukemia (TBI) | Leukemia (No TBI) | P Valuea | |
|---|---|---|---|---|---|---|
| Background | ||||||
| N, male % | N = 139, 56% | N = 270, 59% | N = 224, 75% | N = 72, 62% | N = 52, 75% | <0.001 |
| Birth weight, SDS | -0.2 (-1.5, 1.1) | -0.2 (-1.5, 1.2) | 0.0 (-1.3, 1.1) | 0.1 (-1.5, 1.4) | -0.1 (-1.2, 1.1) | 0.487 |
| Mid-parental height SDS | -0.5 (-2.0, 0.8) | -0.3 (-1.9, 1.1) | -0.2 (-1.5, 1.0) | -0.2 (-1.9, 1.0) | -0.9 (-2.2, 0.8) | 0.004 |
| Maximum GH peak (ng/mL) | 1.5 (0.3, 4.6) | 1.2 (0.2, 4.9) | 4.5 (1.6, 13.0) | 7.3 (2.2, 15.0) | 6.0 (1.4, 14.1) | <0.001 |
| IGF-I SDS | -2.8 (-4.1, -1.3) | -2.7 (-3.8, -1.1) | -2.2 (-3.3, -0.8) | -1.2 (-4.4, 1.4) | -2.8 (-4.8, -2.6) | 0.012 |
| Age at tumor diagnosis, y | 7.9 (4.5, 11.9) | 7.3 (2.9, 11.6) | 6.7 (3.6, 10.3) | 5.3 (1.9, 10.8) | 8.6 (2.4, 11.5) | <0.001 |
| Age at starting cranial irradiation, yb | 6.6 (4.6, 11.5) N = 41 |
5.4 (3.0, 8.0) N = 83 |
- | |||
| Age at starting TBI, yb | - | - | - | 4.7 (2.3, 7.8) N = 43 |
- | |
| Age at surgery, yb | - | 6.8 (2.4, 10.1) N = 100 |
- | - | - | |
| Age at starting chemotherapy, yb | - | - | - | - | 2.6 (0.7, 5.8) N = 15 |
|
| At start of GH therapy | ||||||
| Chronological age, y | 8.3 (5.1, 11.8) | 7.9 (3.6, 11.8) | 8.0 (5.6, 10.6) | 9.5 (6.5, 11.5) | 10.0 (7.1, 11.7) | <0.001 |
| Height SDS, Prader | -2.4 (-3.8, -0.3) | -2.2 (-4.1, -0.4) | -2.0 (-3.6, -0.8) | -2.1 (-3.2, -1.0) | -2.2 (-3.5, -0.9) | 0.528 |
| Height - MPH SDS, Prader | -1.9 (-3.7, 0.1) | -1.8 (-3.6, -0.1) | -1.7 (-3.2, -0.6) | -1.6 (-3.1, -0.7) | -0.9 (-2.8, 0.5) | 0.108 |
| Weight SDS | -0.3 (-2.4, 1.6) | -0.4 (-2.2, 2.2) | -0.8 (-2.2, 0.5) | -1.2 (-2.3, 0.7) | -1.0 (-2.2, 0.8) | <0.001 |
| BMI SDS, CDC/NCHS | 1.2 (-0.5, 2.7) | 1.2 (-0.8, 3.3) | 0.4 (-1.0, 1.6) | -0.1 (-1.4, 1.7) | 0.4 (-1.1, 1.8) | <0.001 |
| GH dose, mg/kg/wk | 0.17 (0.10, 0.25) | 0.18 (0.12, 0.25) | 0.20 (0.14, 0.27) | 0.22 (0.17, 0.31) | 0.18 (0.12, 0.27) | <0.001 |
| At latest reported clinic visit | ||||||
| Age at start of pubertyb | 13.5 (11.0, 16.3) | 13,3 (11.3, 15.7) | 11.5 (9.6, 13.8) | 12.4 (11.2, 14.9) | 12.1 (10.4, 14.7) | <0.001 |
| Duration on GHT, y | 8.1 (5.4, 12.1) | 8.4 (5.5, 12.5) | 7.4 (5.7, 10.8) | 6.9 (5.3, 9.5) | 6.5 (5.4, 9.8) | 0.002 |
| Percent in puberty after 5 y of GHTb | 48% | 44% | 84% | 85% | 86% | <0.001 |
Top panel shows background; middle panel, at start of GHT; and bottom panel, at latest reported clinic visit. Values shown are median (10th, 90th percentiles).
Abbreviations: CDC/NCHS, Centers for Disease Control and Prevention/National Center for Health Statistics; GHT, GH therapy; IGF-I, insulin-like growth factor I; RT, radiation therapy; TBI, total body irradiation; SDS, SD score.
a Kruskal-Wallis test was applied to the continuous background variables, and χ 2 test to the binary variables.
b Based on genital stage (male) testicular volume >3 mL and breast stage ≥2 (female) reported by the investigator at GH start on the case report form.
*Tumor treatment ages were not available for all patients.